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ABSTRACT 
 
Analysis of the Requirements for Human Toll-like Receptor 3 Dominant Negativity and 
Signal Transduction (April 2009) 
 
Matthew Hickey 
Department of Biochemistry 
Texas A&M University 
 
Research Advisor: Dr. Cheng Kao 
Department of Biochemistry 
 
Toll-like receptors are an important part of the innate immune system and mediate 
infection via the recognition of pathogen-associated molecular patterns (PAMPs).  Toll-
like receptor 3 (TLR3) recognizes foreign-derived double stranded RNA as its ligand, 
and is active as a homodimer.  Previous research has indicated that specific residues  in 
TLR3’s extracellular domain (ECD) are responsible for dimer-dimer interactions 
between TLR3s, and the apparent specificity of this interaction has allowed for 
modulation of TLR3 signal through the use of dominant negative mutants.  Here we 
present a class of mutants which lack the inter-disulfide cap region of the ECD (Δ123-
635, hereafter called TLR3N-CT), yet still exhibit dominant negative properties.  The 
degree of dominant negative inhibition of TLR3N-CT is comparable to that of TLR3 
ΔToll interleukin-1 receptor (TIR), the previously established standard for dominant 
negativity.  Tyrosine mutants, such as Y759F, have been shown to dramatically reduce 
TLR3 signal induction by interfering with cytoplasmic signaling adapters.  Our mutant, 
TLR3N-CT Y759F, retained the ability to act as a dominant negative inhibitor of TLR3, 
  iv 
thus indicating that the observed reduction in induced/uninduced signal was not due to 
ligand-independent activation of the mutant.  Furthermore, the mutant TLR3N-CTΔTIR 
was generated to investigate the role of the cytoplasmic TIR domain in dimer-dimer 
interactions.  This mutant was not a dominant negative inhibitor of TLR3 activity, 
indicating a possible role of the TIR domain in the dominant negative interaction 
between TLR3N-CT and wild type TLR3.  It is possible that this TIR-TIR interaction is 
either in the incorrect confirmation for signaling or, contrary to previous reports that 
ligand binding and dimerization are necessary only to bring the TIR domains together, 
that more than simple TIR-TIR interaction is required for TLR3 signaling. However, 
expression studies by western blot have been unable to prove expression by any of the 
mutants previously discussed.  Several explanations are possible, but it is likely that 
expression levels are sufficient for cell-based activity assays but too low for western blot 
detection.  
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NOMENCLATURE 
 
ECD Extracellular domain 
HA hemagglutinin  
LLR leucine rich repeat  
TLR Toll-like receptor 
TLR3N TLR3 with deletion of residues 123-590 
TLR3N-CT TLR3 with deletion of residues 123-635 
PAMP Pathogen associated molecular pattern 
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CHAPTER I 
INTRODUCTION: INNATE IMMUNITY AND TOLL-LIKE 
RECEPTORS 
 
The human immune system is generally divided into two branches: innate and adaptive 
immunity.  The distinction is made based on the specificity of the response and the time 
from the initial recognition of the pathogen to the immune response.  Adaptive immunity 
consists of antigen-specific responses carried out by B and T lymphocytes, and while 
this response is highly pathogen-specific, it takes several weeks to react after the initial 
presence of a pathogen.  Innate immunity, in the broadest sense, can encompass all 
barriers to infection, such as skin as a physical barrier and lysozyme as an antimicrobial 
barrier, however the focus generally rests on the more cell-based responses of innate 
immunity.  These responses can take place within a few hours but are not pathogen-
specific; the innate response is much more systemic and results in a number of unwanted 
side effects, such as inflammation (1). 
 
The innate immune system is initiated by receptors that can recognize pathogen-
associated molecular patterns (PAMPs) and will, in turn, induce signal transduction to 
lead to the production of defense molecules (2). The Toll-like receptors (TLRs) are  
 
_____________________ 
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among this family of receptors.  TLR3, the subject of this research, recognizes pathogen 
derived double-stranded (ds) RNA, a product of the replication for many viruses (2). 
 
TLR3 is a single pass transmembrane protein that contains a ligand binding extracellular 
domain (ECD), the transmembrane domain (TM), and the intracellular domain (ICD) 
which can recruit kinases required for signal transduction.  The ECD consists of N-
terminus and C-terminus disulfide bond-capped ends as well as the binding site for 
dsRNA (4, 5). 
 
Previous research has revealed that ligand binding by TLR3 induces the oligomerization 
required for signaling (6).  Ligand binding takes place between the N- and C-terminal 
portions of the TLR3 ECD and includes residue E543. However, oligomerization should 
require the interaction of two or more TM domains (7, 8).  Following ligand binding and 
dimerization, activated TLR3 recruits signal adaptor molecules and leads to the 
activation of the transcription factor NF-κB and the production of type I interferon (IFN) 
and proinflammatory cytokines (2). TLR3 may also be involved in a number of human 
diseases that are not necessarily mediated by pathogens, such as macular degeneration 
(10). 
 
The ability to regulate TLR3 and the ensuing inflammatory response could be applied 
toward mitigating diseases. For example, suppressing TLR signaling could decrease the 
cytokines and chemokines that cause many symptoms.  However, there is also need to 
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maintain some level of TLR3, as patients without functional TLR3 are subject to severe 
symptoms in association to gamma-herpes virus infection (3). A human single 
nucleotide polymorphism that decreases signaling by TLR3 has been linked to decreased 
incidence of the dry form of macular degeneration (10).  The various roles of TLR3 in 
viral infection and human disease outcomes point toward a clear usefulness in 
modulating its activity. 
 
My research is to understand how TLR3 recognizes ligand and activates signal 
transduction.  The original hypothesis was that elimination of the ECD dimerization 
domain should result in a molecule containing the TM and ICD that could still interact 
with wild type TLR3.  This interaction would result in one of two outcomes.  One is that 
this ECD mutant will act in a dominant negative manner when it is complexed with the 
wild-type TLR3.  A second possibility is that this interaction will result in a 
constitutively active (ligand independent) complex due to the loss of the normal ligand-
dependent regulatory mechanisms.  This research explores this interaction between wild 
type TLR3 and mutations of TLR3 that contain in frame truncations of the ECD. 
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CHAPTER II 
EXPERIMENTAL PROCEDURES 
 
Plasmid Construction 
 
Stocks of wild type human TLR3 (GenBank accession number U88879) were obtained 
from Ranjith-Kumar.  This TLR3 cDNA was cloned into the pcDNA3.1 vector as 
described previously (11).  Using this construct, several TLR3 mutants were constructed: 
TLR3N and TLR3N-CT which include large deletions, and various point mutations of 
the wild type and TLR3N/TLR3N-CT constructs. In addition, hemaglutinin epitope-
tagged versions of all previous constructs were made to allow detection of expression 
through western blotting.  
 
Preparation of TLR3N and TLR3N-CT mutants 
With the goal of eliminating the entire region between the N- and C-terminus disulfide 
“caps” of the extracellular region of TLR3, oligonucleotides were designed to introduce 
restriction enzyme recognition sites on either side of this region.  Oligonucleotides 1 and 
2 were first used to amplify the N-terminus region of the TLR3 ECD (Table 1).  This 
amplified region included a NheI restriction site on the 5’ end, while oligonucleotide 2 
was designed to add an additional EcoRI and ClaI restriction cut site to the 3’ end.  The 
PCR product was generated by use of the Pfu polymerase, and then inserted into a 
pGEMT-easy vector (Promega Inc.).  The pGEMT vector approach was chosen due to 
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difficulty encountered in trying to directly digest and ligate the short fragment back into 
the TLR3 vector.  Following amplification and plasmid purification of the pGEMT 
constructs, they were digested with the restriction enzymes NheI and ClaI (New England 
Biosystems).  The digested DNAs were then loaded on a 1.5% agarose gel to separate 
the amplified region from the larger vector.  Correct pGEM-T insertions yielded two 
bands running at 400 bp and 3 kb, while correct pcDNA-TLR3 digestions yielded two 
bands running at 1.8 kb and 6.5 kb.  The 400 bp pGEM-T fragment and the 6.5 kb 
pcDNA-TLR3 fragment were each then purified using a gel extraction kit (Qiagen), and 
ligated using T4 DNA ligase, resulting in the completed TLR3N construct.  DNA 
sequencing was employed to confirm the correct construction of this mutant. 
 
The TLR3N mutant removed the majority of the TLR3 ECD, but left the N- and C-
terminal caps and leucine rich repeats (LLRs) 21 to 23 (4).  To remove all of the 
uncapped LRRs, oligonucleotides 3 and 4 were designed to insert an EcoRI site at the 5’ 
end of the C-terminus ECD disulfide cap and to amplify through the naturally occurring 
XhoI site.  The resulting PCR product and the TLR3N construct were both digested with 
EcoRI and XhoI and ligated together to form the TLR3N-CT construct.  This was 
sequenced to ensure that no unintended mutations were made. 
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Table 1. Primers used for plasmid construction 
Primer 
Name Primer Sequence Purpose 
1 5'- GGCTAGCAGTCATCCAACAGAATC -3' To add ClaI and EcoRI resctriction enzyme sites to the 3' end of the ECT 
N-terminal cap of TLR3 for use in 
ligating this region with the C-
terminal cap of the TLR3 ECD 
2 5'- TCATCGATGAATTCGCAGAAGGCAAAGGTTTTATCAGAAAG -3' 
3 5'- AAAGAATTCAACCTGACTGAGTTAG ATATGCGCTTTAATCC -3' 
To add an EcoRI restriction site to the 
5' end of the C-terminal TLR3 ECD 
cap in order to ligate this with the 
EcoRI site inserted on the 3' end of the 
N-terminal cap 
4 5'- GATGCTGTTAACAATTGCTTCTAGTTCAAAAACACC -3' 
dTIR 1 5'- GACAGAACAGTTTGAATAGGCAGCAT ATATAATTCATG -3' 
To change the Tyr residue at position 
756 in wild type TLR3 to a stop codon 
dTIR 2 5'- CATGAATTATATATGCTGCCTATTCAAACTGTTCTGTC -3' 
Y759F 
1 5'- CAGAACAGTTTGAATATGCAGCATTTA TAATTCATGCC -3' 
To change the Tyr residue at position 
759 in wild type TLR3 to a 
Phenylananine.  This Tyr is an 
important phosphorylation site for 
TLR3 signaling 
Y759F 
2 5'- GGCATGAATTATAAATGCTGCATATTCAAACTGTTCTG -3' 
HA 1 5'- GAATCATGTACCCGTACGACGTCCCGGACTACGCCAGACAGAC TTTGCCTTGTATCTACTTTTGGG -3' Adds the HA epitope, YPYDVPDYA 
to the N-terminal side of TLR3 
HA 2 5'- CTGTCTGGCGTAGTCCGGGACGTCGTACGGGTACATGATTCTGT TGGATGACTGCTAGCCTTTCC -3' 
* non-complimentary additions are highlighted, added restriction sites are underlined 
 
 
Single nucleotide polymorphisms 
Point mutations in the TIR signaling domain were generated in both wild type TLR3 and 
TLR3N-CT, resulting in the mutant forms of Y759F and a missense mutation, known as 
ΔTIR, which prevents the transcription of the TIR domain coding region of the gene.  
Oligonucleotides were designed to make the appropriate single base pair substitutions 
(Table 1) and Pfu polymerase was used for the PCR mutagenesis reaction.  All mutants 
were sequenced across mutation sites to ensure that no unintended alterations were 
made.  Resulting mutants were TLR3ΔTIR, TLR3 Y759F, TLR3NΔTIR, TLR3N 
Y759F, TLR3N-CTΔTIR, and TLR3N-CT Y759F. 
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HA-tagged mutants 
In order to aid in the detection of these, at times severely altered, mutants, an HA tag 
(sequence YPYDVPDYA) was attached to the N-terminal side of each mutant.  
Oligonucleotides containing the insertion were generated and extended around each 
plasmid using Pfu polymerase (Table 1).  Each mutant was sequenced across the HA 
insertion to ensure that no unintended alterations were made. 
 
Cell-based reporter assay for TLR3 signaling 
 
Methods for this assay were adapted from those reported by Sun, et al. (11).  Briefly, 
HEK 293T cells were plated on a CoStar White plates at 1.5 x105 cells/mL with a total 
of 200 μL per well.  Following incubation at 37°C in 5% CO2 until the cells were 65-
90% confluent, the cells were transfected with a mixture of Lipofectamine 2000 reagent 
(Invitrogen) and plasmids pNF-κβ-Luc (Stratagene Inc., La Jolla, CA) or ISRE-Luc, 
wild type or mutant TLR3, and phRL-TK (Promega Corp., Madison, WI).  pNF-κβ-Luc 
and ISRE-Luc are both downstream transcription factors for the TLR3 signal 
transduction pathway and are attached to a firefly luciferase reporter.  phRL-TK is a 
constitutively active gene attached to a Renilla luciferase reporter and is used for 
transfection control.  Following transfection, the cells were incubated for 24 h at 37°C in 
5% CO2.  At this time, the supernatant was discarded and the cells are induced with 
poly(I:C) at a concentration of 2.5 μg/mL.  After 6 hours of induction, the cells were 
treated with Dual Glo Luciferase Assay System reagents (Promega).  The resulting 
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luminescence, derived from plasmid expression, was quantified using the FLU-Ostar 
OPTIMA Plate Reader (BMG Labtech, Inc). 
 
Western blotting 
 
HEK 293T cells were transfected with Lipofectamine 2000 reagent (Invitrogen) and the 
plasmid of interest.  Following an incubation of 24 hours, cells were lysed using lysis 
buffer (Promega Inc.) and sonicated to decrease the viscosity of the solution.  Cell 
lysates were then combined with a protein loading buffer and loaded on a NuPAGE 4-
12% bis-tris gel (Invitrogen).  The iBlot Dry Blotting System (Invitrogen) was used to 
transfer protein samples to an iBlot-supplied polyvinylidene difluoride membrane.  This 
membrane was probed with either polyclonal anti-TLR3 or monoclonal anti-HA 
antibody, followed by a peroxidase-conjugated secondary antibody.  Blots were 
developed using the ECL Plus Western blotting detection system (Amersham 
Biosciences). 
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CHAPTER III 
RESULTS AND DISCUSSION 
 
Results and Discussion 
 
Inter-cap ECD deletion exhibits dominant negative inhibition of wild type TLR3 
As would be expected, TLR3N-CT was unable to induce signaling when expressed in 
cells. However, when co-expressed with the wild type TLR3, it was able to reduce 
signaling by the WT activity.  A control for this reaction is the construct TLR3-ΔTIR, a 
known dominant negative mutant (6) [Fig. 1]. In fact, TLR3N-CT had comparable 
dominant negative activity to TLR3-ΔTIR.  The assay for TLR3 signal activation uses a 
firefly luciferase reporter expressed from either an NF-kB or ISRE promoter that is 
known to be responsive to TLR3. Renilla luciferase expressed from a constitutive 
promoter was used as a transfection control and all firefly luciferase signal was 
normalized over Renilla signal.  HEK293T cells were used because they do not contain 
any endogenous TLR3 (12). Activity is reported as a fold induction of poly I:C 
induced/uninduced normalized signal. 
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FIGURE 1. TLR3N and TLR3N-CT act as dominant negatives to wt TLR3. (a)TLR3N-CT 
demonstrates dominant negativity similar to that of a previous mutant, TLR3N (deletion of residues 
123-590). Results were obtained 6 hours after induction with poly I:C. (b) TLR3N demonstrates 
dominant negativity similar to that of TLR3ΔTIR. Results were obtained 24 hours after induction with 
poly I:C. All samples were normalized with pcDNA to ensure equal plasmid concentration amongst 
samples of the same trial. Different induction times are a result of a procedural change to shorter 
times in attempts to reduce background effects. 
FIGURE 2. Ligand independent activation of TLR3N-CT. Increase in ligand 
independent activation represents potential cause of decrease in fold induction for 
firefly/renilla luciferase ratio (fold induction) observed in Figure 1. All samples 
include 2ng wild-type TLR3. Results were obtained 6 hours after induction with 
poly I:C. 
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In addition to the observed reduction in signal transduction when TLR3N-CT is 
cotransfected with WT TLR3, ligand independent activation is also observed [Fig. 2].  
The decrease in ligand-induced signal and increase in ligand-independent activation 
points toward two potentially coincident explanations for TLR3N-CT activity. 
 
TIR phosphorylation site mutant TLR3N-CT Y759F 
 It has been previously reported that the mutation Y759F in wild type TLR3 results in a 
sharp decline in TLR3 signaling (9).  This is likely due to decreased ability to interact 
with signal adapter molecules.  Here, the mutant TLR3N-CT Y759F was constructed to 
determine whether ligand-independent activation was responsible for the decrease in 
fold induction observed with the co-transfection of TLR3N-CT and WT TLR3.  As 
shown in Figure 3, the removal of this phosphorylation site in the TLR3N-CT mutant 
had no effect on its dominant negative properties.   
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FIGURE 3. TLR3N-CT Y759F dominant negativity and ligand-independent activity. Results 
were obtained 6 hours after induction with poly I:C. (A)  TLR3N-CT Y759F exhibits similar 
dominant negativity to TLR3N-CT mutant.  (B) While some ligand-independent activation is still 
evident, TLR3N-CT Y759F lacks the primary phosphorylation site for TIR activation, indicating 
that any ligand-independent activation present is due to causes aside from TLR3 manipulation. 
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Because TLR3 signal induction is mediated through cytoplasmic tyrosine residues, it is 
thought that a Y759F mutant will silence any potential ligand-independent activation 
observed in the TLR3N-CT mutant.  From Figure 3, it is apparent that TLR3N-CT 
Y759F retains dominant negative activity.  This result indicates that the dominant 
negative properties of both TLR3N-CT and TLR3N-CT Y579F are not likely to be 
caused by ligand-independent activation. 
 
TIR domain deletion – TLR3N-CT ΔTIR 
Based on the observation that dominant negative interaction was occurring with the 
TLR3N-CT mutant despite the fact that the dimerization domain was missing, it became 
necessary to determine which domains were interacting.  Figure 4 demonstrates that the 
removal of the TIR domain from the TLR3N-CT ECD mutant results in the loss of 
dominant negative properties.  This observation leads to two possible conclusions.  The 
first is that the TIR domain contains a secondary dimerization site which allows for 
dominant negative interaction when the sterically bulky ECD is not present.  The loss of 
the putative dimer interaction explains the loss of dominant negativity reported in Figure 
4.  Alternatively, the loss of dominant negative activity could be due to an effect on 
expression. 
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HA-tagging for expression studies 
Due to the significant manipulation of wild-type TLR3 to obtain some of the mutants 
used in these experiments, an alternative to the use of a polyclonal αTLR3 antibody was 
necessary to ensure detection of protein expression by western blot.  As a convenient 
solution to this problem, each mutant and wild-type protein described above was tagged 
with the hemagglutinin (HA) protein of sequence YPYDVPDYA.  Figure 5 
demonstrates the dominant negative properties of each of these HA-tagged mutants as 
compared with their untagged counterparts.  The comparible dominant negativity of each 
of the HA mutants to their counterparts indicates that the HA tag had no significant 
disruptive effect on the activity and interactions of the mutants. 
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FIGURE 4. Dominant negativity is lost in TLR3N-CT ΔTIR. The deletion of the TIR domain in 
TLR3N and TLR3N-CT results in a loss of dominant negative interaction with wt TLR3. Results were 
obtained 6 hours after induction with poly I:C. 
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FIGURE 5. Dominant negativity of HA-tagged mutants. Renillia/Luciferase assay comparing 
dominant negativity of HA-tagged mutants to their untagged counterparts.  Reporter genes are ISRE 
(A) and NFκB (B).  Results were obtained 6 hours after induction with poly I:C. 
TLR3 mutant activity 
It was necessary to prove that none of the mutants used in these dominant negativity 
assays were themselves able to be activated.  To examine this, each mutant was 
transfected individually into HEK293T cells and then induced according to the above 
protocol.  Figure 6 reports the signal induction in response to poly I:C. 
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Expression analysis by western blot 
Western blots were conducted in order to establish the expression of the mutants studied 
in these experiments.  In order to detect the wild type and HA-tagged ECD mutants, both 
a polyclonal αTLR3 antibody and an αHA antibody were used.  After several trials with 
αTLR3, no expression could be found in any of the mutants or wild type strains (data not 
shown).  Positive controls of pBeth HA-TLR3 and pcDNA TLR3 ECD were detected.  
The αHA was unable to detect expression for even the positive controls, despite several 
attempts and successful uses by other lab members.  The lack of expression as reported 
by western blot leaves room for several possible explanations.  It is, of course, possible 
that none of these mutants are being expressed and that all activity assay data is merely 
an artifact of some unknown alternative variable.  However, this explanation is 
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FIGURE 6. Signal induction from various TLR3 mutants. Each mutant was individually 
transfected into HEK293T-cells, and following induction with poly I:C signal fold induction was 
measured. Results were obtained 6 hours after induction with poly I:C.
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unsatisfactory for several reasons.  First, the ability of wild type TLR3 and reduced 
ability of the mutants to induce ISRE/NFκΒ lends credence to the argument that the 
TLR3 mutants used in these experiments are expressive.  Secondly, since wild type 
TLR3 can ordinarily be detected by αTLR, the question shifts away from whether or not 
the particular genes are expressed to whether or not the western procedure is being 
conducted correctly and whether the plasmids are working correctly.  Since the western 
was repeated several times with the same results, it is unlikely that procedural errors are 
to blame.  Both of these observations do lead, however, to the possibility of a promoter 
mutation on all of the plasmids.  The presence of such a mutation could explain a level 
of expression which is sufficient to detect ligand, but not sufficient to be detected by 
western blot.    
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CHAPTER IV 
CONCLUSION 
 
The ability to modulate TLR3 activity through dominant negative inhibition holds 
promise for better understanding and controlling of human inflammatory disease.  This 
research specifically advances the study of TLR3 by identifying a potential new mutant 
which exhibits a new mechanism for dominant negativity.   The problems of expression 
still need to be resolved in order to validate the promise of this new mutant class for 
modulation of TLR3 signaling. 
 
Previous research has proposed that dominant negative interaction occurs at the 
dimerization site in the ECD (7).  These conclusions were based on the observed loss of 
dominant negative inhibition in mutants containing a substitution in proposed 
dimerization residues, such as E442K (7), however this research provides evidence that 
this interaction may be more complex than originally thought.  Since, the mutants 
studied here lack any contribution or opposition to dimerization at the originally 
proposed ECD sites, the role of the TIR and transmembrane domains in dimerization can 
be observed. 
 
Beyond the unsolved expression issues, there are still several other questions left 
unanswered by this research.  It remains unclear which portion of the TLR3N-CT mutant 
is contributing to its dominant negative interactions.  If expression data can be obtained, 
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this data will help elucidate whether or not the lack of dominant negative inhibition by 
TLR3N-CTΔTIR is due to lack of protein expression or to the presence of a secondary 
dimerization domain in the TIR domain.  If TLR3N-CT is expressed, further 
experimentation will then be necessary to determine whether these mutants are folding 
correctly and whether their dominant negative interactions are in the same orientation as 
wild type TLR3 dimer interactions.  The orientation in which these mutants are 
interacting is of interest for a better understanding of both wild type TLR3 interactions 
and of domains which could be manipulated to modulate wild type signaling. 
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